Company Overview of Genelux Corporation
Genelux Corporation, a biomedical company, develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. Its product GL-ONC1 is a genetically stable oncolytic virus strain to locate, enter, colonize, and destroy cancer cells without harming healthy tissues or organs. Genelux Corporation was founded in 2001 and is headquartered in San Diego, California. The company has locations in Redlands, California; and Bernried, Germany.
3030 Bunker Hill Street
San Diego, CA 92109 5754
Founded in 2001
Key Executives for Genelux Corporation
Chief Executive Officer, President, Chief Compliance Officer and Director
Founder, Chairman Emeritus and Chief Scientific Advisor To The Chief Executive Officer
Chief Operating Officer, Director, Member of Scientific Advisory Board and Member of Clinical Advisory & Implementation Board
Chief Executive Officer of Genelux Europe and President of Genelux Europe
Compensation as of Fiscal Year 2014.
Genelux Corporation Key Developments
Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM
Apr 11 15
Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Genelux Announces Board Appointments
Jun 9 14
Genelux has appointed George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux, to the company's Board of Directors. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corp. Board to nine members.
Genelux Corporation Announces Board Changes
May 28 14
Genelux Corporation announced the appointment of Mr. George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux Corporation, to the company's Board of Directors. Mr. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corporation Board to nine members. Vandeman retired in 2000 after five years at Amgen as Senior Vice President, General Counsel and Chairman of the company's Operating Committee. Thomas Zindrick, also named to the Board of Directors, was recently appointed CEO and president of Genelux Corporation, succeeding founder and former CEO and President, Aladar A. Szalay, Ph.D. Prior to Genelux, Mr. Zindrick was CEO of Amitech Therapeutic Solutions Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|